{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:59:35Z","timestamp":1791874775894,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,2,20]]},"DOI":"10.1038\/bjc.2017.442","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T23:46:20Z","timestamp":1516319180000},"page":"509-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma"],"prefix":"10.1038","volume":"118","author":[{"given":"Hailong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijie","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"BFbjc2017442_CR1","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s12032-012-0159-2","volume":"29","author":"M Agulnik","year":"2012","unstructured":"Agulnik M (2012) New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol 29: 2481\u20132491.","journal-title":"Med Oncol"},{"key":"BFbjc2017442_CR2","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1158\/0008-5472.CAN-12-3788","volume":"73","author":"N Bacher","year":"2013","unstructured":"Bacher N, Raker V, Hofmann C, Graulich E, Schwenk M, Baumgrass R, Bopp T, Zechner U, Merten L, Becker C, Steinbrink K (2013) Interferon-alpha suppresses cAMP to disarm human regulatory T cells. Cancer Res 73: 5647\u20135656.","journal-title":"Cancer Res"},{"key":"BFbjc2017442_CR3","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1158\/0008-5472.CAN-16-0754","volume":"77","author":"F Braig","year":"2017","unstructured":"Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Markl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M (2017) Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism. Cancer Res 77: 1188\u20131199.","journal-title":"Cancer Res"},{"key":"BFbjc2017442_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1158\/1078-0432.CCR-05-1671","volume":"12","author":"F Bruzzese","year":"2006","unstructured":"Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A (2006) Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 12: 617\u2013625.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017442_CR5","first-page":"1294","volume":"51","author":"A Budillon","year":"1991","unstructured":"Budillon A, Tagliaferri P, Caraglia M, Torrisi MR, Normanno N, Iacobelli S, Palmieri G, Stoppelli MP, Frati L, Bianco AR (1991) Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res 51: 1294\u20131299.","journal-title":"Cancer Res"},{"key":"BFbjc2017442_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/sj.cdd.4400550","volume":"6","author":"M Caraglia","year":"1999","unstructured":"Caraglia M, Abbruzzese A, Leardi A, Pepe S, Budillon A, Baldassare G, Selleri C, Lorenzo SD, Fabbrocini A, Giuberti G, Vitale G, Lupoli G, Bianco AR, Tagliaferri P (1999) Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 6: 773\u2013780.","journal-title":"Cell Death Differ"},{"key":"BFbjc2017442_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ijc.2910610312","volume":"61","author":"M Caraglia","year":"1995","unstructured":"Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, Guarrasi R, Bianco AR, Tagliaferri P (1995) alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 61: 342\u2013347.","journal-title":"Int J Cancer"},{"key":"BFbjc2017442_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401\u2013404.","journal-title":"Cancer Discov"},{"key":"BFbjc2017442_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621\u2013681.","journal-title":"Pharmacol Rev"},{"key":"BFbjc2017442_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/jir.2008.0079","volume":"29","author":"A Diaz","year":"2009","unstructured":"Diaz A, Batista AE, Montero E (2009) Interferon-alpha conditioned sensitivity to an anti-epidermal growth factor receptor monoclonal antibody in a human lung cancer cell line with intermediate expression of the receptor. J Interferon Cytokine Res 29: 433\u2013440.","journal-title":"J Interferon Cytokine Res"},{"key":"BFbjc2017442_CR11","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1210\/jc.2016-1882","volume":"101","author":"S Fang","year":"2016","unstructured":"Fang S, Huang Y, Wang S, Zhang Y, Luo X, Liu L, Zhong S, Liu X, Li D, Liang R, Miranda P, Gu P, Zhou H, Fan X, Li B (2016) IL-17\u2009A exacerbates fibrosis by promoting the proinflammatory and profibrotic function of orbital fibroblasts in TAO. J Clin Endocrinol Metab 101: 2955\u20132965.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFbjc2017442_CR12","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1.","journal-title":"Sci Signal"},{"key":"BFbjc2017442_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccr.2013.11.011","volume":"25","author":"J Hou","year":"2014","unstructured":"Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng IO, Sun H, Qin L, Qiu S, Lee JM, Lo CM, Man K, Yang Y, Yang Y, Yang Y, Zhang Q, Zhu X, Li N, Wang Z, Ding G, Zhuang SM, Zheng L, Luo X, Xie Y, Liang A, Wang Z, Zhang M, Xia Q, Liang T, Yu Y, Cao X (2014) Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 25: 49\u201363.","journal-title":"Cancer Cell"},{"key":"BFbjc2017442_CR14","doi-asserted-by":"publisher","first-page":"e58273","DOI":"10.1371\/journal.pone.0058273","volume":"8","author":"J Hu","year":"2013","unstructured":"Hu J, He Y, Yan M, Zhu C, Ye W, Zhu H, Chen W, Zhang C, Zhang Z (2013) Dose dependent activation of retinoic acid-inducible gene-I promotes both proliferation and apoptosis signals in human head and neck squamous cell carcinoma. PLoS One 8: e58273.","journal-title":"PLoS One"},{"key":"BFbjc2017442_CR15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc1913","volume":"6","author":"K Imai","year":"2006","unstructured":"Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714\u2013727.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017442_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.yexcr.2015.11.013","volume":"339","author":"SF Jin","year":"2015","unstructured":"Jin SF, Ma HL, Liu ZL, Fu ST, Zhang CP, He Y (2015) XL413, a cell division cycle 7 kinase inhibitor enhanced the anti-fibrotic effect of pirfenidone on TGF-beta1-stimulated C3H10T1\/2 cells via Smad2\/4. Exp Cell Res 339: 289\u2013299.","journal-title":"Exp Cell Res"},{"key":"BFbjc2017442_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-presentation by dendritic cells. Nat Rev Immunol 12: 557\u2013569.","journal-title":"Nat Rev Immunol"},{"key":"BFbjc2017442_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3892\/mmr.2014.2046","volume":"9","author":"W Li","year":"2014","unstructured":"Li W, Wei Q, Liang J (2014a) Phosphorylated signal transducer and activator of transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma. Mol Med Rep 9: 1929\u20131934.","journal-title":"Mol Med Rep"},{"key":"BFbjc2017442_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.molcel.2013.12.008","volume":"53","author":"XY Li","year":"2014","unstructured":"Li XY, Jiang LJ, Chen L, Ding ML, Guo HZ, Zhang W, Zhang HX, Ma XD, Liu XZ, Xi XD, Chen SJ, Chen Z, Zhu J (2014b) RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness. Mol Cell 53: 407\u2013419.","journal-title":"Mol Cell"},{"key":"BFbjc2017442_CR20","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.7150\/jca.19486","volume":"8","author":"H Ma","year":"2017","unstructured":"Ma H, Jin S, Yang W, Tian Z, Liu S, Wang Y, Zhou G, Zhao M, Gvetadze S, Zhang Z, Hu J (2017a) Interferon-alpha promotes the expression of cancer stem cell markers in oral squamous cell carcinoma. J Cancer 8: 2384\u20132393.","journal-title":"J Cancer"},{"key":"BFbjc2017442_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-017-0575-4","volume":"36","author":"HL Ma","year":"2017","unstructured":"Ma HL, Jin SF, Ju WT, Fu Y, Tu YY, Wang LZ, Jiang L, Zhang ZY, Zhong LP (2017b) Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma. J Exp Clin Cancer Res 36: 109.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFbjc2017442_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.oraloncology.2015.02.092","volume":"51","author":"J Martinez-Useros","year":"2015","unstructured":"Martinez-Useros J, Garcia-Foncillas J (2015) The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncol 51: 423\u2013430.","journal-title":"Oral Oncol"},{"key":"BFbjc2017442_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1600-0609.2007.00968.x","volume":"79","author":"H Meng","year":"2007","unstructured":"Meng H, Yang C, Ni W, Ding W, Yang X, Qian W (2007) Antitumor activity of fludarabine against human multiple myeloma in vitro and in vivo. Eur J Haematol 79: 486\u2013493.","journal-title":"Eur J Haematol"},{"key":"BFbjc2017442_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrc.2016.14","volume":"16","author":"BS Parker","year":"2016","unstructured":"Parker BS, Rautela J, Hertzog PJ (2016) Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16: 131\u2013144.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017442_CR25","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1200\/JCO.2015.62.0963","volume":"33","author":"AG Sacco","year":"2015","unstructured":"Sacco AG, Cohen EE (2015) Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33: 3305\u20133313.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017442_CR26","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/hed.21365","volume":"32","author":"ME Sharafinski","year":"2010","unstructured":"Sharafinski ME, Ferris RL, Ferrone S, Grandis JR (2010) Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32: 1412\u20131421.","journal-title":"Head Neck"},{"issue":"10","key":"BFbjc2017442_CR27","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/neuonc\/nox051","volume":"19","author":"M Silginer","year":"2017","unstructured":"Silginer M, Nagy S, Happold C, Schneider H, Weller M, Roth P (2017) Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma. Neuro Oncol 19 (10): 1338\u20131349.","journal-title":"Neuro Oncol"},{"key":"BFbjc2017442_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.20131556","volume":"211","author":"S Srivastava","year":"2014","unstructured":"Srivastava S, Koch MA, Pepper M, Campbell DJ (2014) Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection. J Exp Med 211: 961\u2013974.","journal-title":"J Exp Med"},{"key":"BFbjc2017442_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116\u20131127.","journal-title":"N Engl J Med"},{"key":"BFbjc2017442_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S1470-2045(13)70181-5","volume":"14","author":"JB Vermorken","year":"2013","unstructured":"Vermorken JB, Stohlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S, Skladowski K, Tahara M, Pai VR, Faivre S, Blajman CR, Forastiere AA, Stein BN, Oliner KS, Pan Z, Bach BA (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14: 697\u2013710.","journal-title":"Lancet Oncol"},{"key":"BFbjc2017442_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrg1315","volume":"5","author":"WW Wasserman","year":"2004","unstructured":"Wasserman WW, Sandelin A (2004) Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 5: 276\u2013287.","journal-title":"Nat Rev Genet"},{"key":"BFbjc2017442_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coi.2016.05.016","volume":"42","author":"M Weber-Gerlach","year":"2016","unstructured":"Weber-Gerlach M, Weber F (2016) Standing on three legs: antiviral activities of RIG-I against influenza viruses. Curr Opin Immunol 42: 71\u201375.","journal-title":"Curr Opin Immunol"},{"key":"BFbjc2017442_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1517\/14728214.2015.1031653","volume":"20","author":"Y Wen","year":"2015","unstructured":"Wen Y, Grandis JR (2015) Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs 20: 313\u2013329.","journal-title":"Expert Opin Emerg Drugs"},{"key":"BFbjc2017442_CR34","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/j.1464-410X.2007.06778.x","volume":"99","author":"JL Yang","year":"2007","unstructured":"Yang JL, Qu XJ, Hayes VM, Brenner PC, Russell PJ, Goldstein D (2007) Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha. BJU Int 99: 1539\u20131545.","journal-title":"BJU Int"},{"key":"BFbjc2017442_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2004.11.041","volume":"225","author":"JL Yang","year":"2005","unstructured":"Yang JL, Qu XJ, Russell PJ, Goldstein D (2005) Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Lett 225: 61\u201374.","journal-title":"Cancer Lett"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017442","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017442.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:40:47Z","timestamp":1684417247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2,20]]}},"alternative-id":["BFbjc2017442"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.442","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,18]]},"assertion":[{"value":"3 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}